Mutations in the miR-142 gene are not common in myeloproliferative neoplasms

Paulina Galka-Marciniak1, Zuzanna Kanduła2, Adrian Tire1, Władysław Wegorek2, Kinga Gwozdz-Bak2, Luiza Handschuh1,3, Maciej Giefing4, Krzysztof Lewandowski2 & Piotr Kozlowski1

Recent data indicate that MIR142 is the most frequently mutated miRNA gene and one of the most frequently mutated noncoding elements in all cancers, with mutations occurring predominantly in blood cancers, especially diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Functional analyses show that the MIR142 alterations have profound consequences for lympho- and myelopoiesis. Furthermore, one of the targets downregulated by miR-142-5p is CD274, which encodes PD-L1 that is elevated in many cancer types, including myeloproliferative neoplasms (MPNs). To extend knowledge about the occurrence of MIR142 mutations, we sequenced the gene in a large panel of MPNs (~700 samples, including polycythemia vera, essential thrombocythemia, primary myelofibrosis (PMF), and chronic myeloid leukemia), neoplasm types in which such mutations have never been tested, and in panels of acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). We identified 3 mutations (one in a PMF sample and two others in one CLL sample), indicating that MIR142 mutations are rare in MPNs. In summary, mutations in MIR142 are rare in MPNs; however, in specific subtypes, such as PMF, their frequency may be comparable to that observed in CLL or AML.

The miR-142 gene (MIR142) along with the well-known TERT promoter has recently been recognized as the most convincingly documented noncoding element consistently mutated in cancer1,2,3. However, unlike the TERT promoter, which is commonly mutated in almost all human malignancies3, MIR142 is mutated almost exclusively (specifically) in lymphoid and myeloid malignancies, including chronic lymphocytic leukemia (CLL; 1–4%), follicular lymphoma (FL; 14–25%), diffuse large B-cell lymphoma (DLBCL; 20–27%), and acute myeloid leukemia (AML; 0.5–2% of cases) (1, references therein).

Our recent cumulative study showed that although these mutations are distributed over the entire MIR142 gene (i.e., the sequence coding for the stem-loop structure of the pre-miR-142 precursor, including flanks), they mostly cluster around the miR-142-3p seed4 and are strongly enriched in hematologic malignancies, which suggests that the mutations are functionally deleterious. Functional analysis of specific mutations (n.55A > G and n.58G > C) located in the miR-142-3p seed revealed that the mutations affect the miRNAs generated from both arms, resulting in loss of the ability of miR-142-3p to recognize/downregulate its targets and in lowering the level of miR-142-5p. More specifically, it was shown that by releasing repression of ASH1L (target of miR-142-3p), MIR142 mutations cause sustained HOXA9/A10 expression and alteration in the differentiation of hematopoietic progenitors (myeloid cell lines expansion, impaired erythropoiesis, and T cell lymphopenia), ultimately contributing to leukemic transformation5. It was also shown in the mouse model that mutations in MIR142 synergize with mutations in Idh2 to initiate AML5,6. It may be expected that deleterious MIR142 mutations also affect other well-documented hematologic targets of miR-142-3p or miR-142-5p, including RAC1 (Rac Family Small GTPase 1)5, PROM1 encoding CD133 antigen5, TNFRSF13C encoding B cell-activating factor receptor (BAFF-R)6, SOCS1 (Suppressor of Cytokine Signaling 1)6,7, PTEN (Phosphatase And Tensin Homolog)5,6, IL6 (Interleukin 6)8 and CD274 encoding programmed death-ligand 1 (PD-L1)5,8,9 which is an important immune checkpoint molecule that is elevated in many cancers, including different types of MPNs5,8,9. In light of results to date, miR-142 has emerged as an antitumor immunity-regulating factor important in different types of blood cancers, mostly lymphoid neoplasms.
In this study, to extend and complement knowledge about the occurrence and/or frequency of MIR142 mutations in hematologic cancers, we sequenced MIR142 in large panels of MPNs [including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic myeloid leukemia (CML)], blood disorders for which such mutations have never been tested, and in AML and CLL, for which the mutations have been reported.

Methods

Cancer sample collection. We analyzed DNA from 929 confirmed blood cancer samples diagnosed at the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poland (collected in 2018–2021). The DNA was extracted from the patient’s peripheral blood cells using Syngen Blood/Cell Mini kit (Syngen Biotech, Poland). The study was approved by the Bioethics Committee of the Poznan University of Medical Sciences, Poland (No. 1037/09, 1056/16, 181/18, 846/21) and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients enrolled in this study. The samples were anonymized and then analyzed.

Mutation nomenclature and target prediction. All mutations were designated (i) according to the Human Genome Variation Society (HGVS) nomenclature in relation to miRNA precursors, as deposited in miRBase release 22.1 and (ii) according to genomic position (hg38). Note that as MIR142 is encoded by the minus strand, the nucleotide numbering in HGVS and genomic annotations is in the opposite directions; additionally, substitution designations are complementary to each other, e.g., A>G in the genome annotation is T>C in the transcript-based (HGVS) annotation. miRNA target predictions were performed with the TargetScan Custom (release 5.2) online tool.

miRNA gene amplification and Sanger sequencing. The miR-142 gene was amplified by PCR using the following primers, miR142_F: 5’CTCACCCGTCAACAGGGTGCT3’, miR142_R: 5’CTCTGGGACGGAGAGTCAGG3’ (231 bp product, annealing temperature 60 °C), enabling sequencing of the entire pre-miR-142 sequence together with ±25 nt flanking regions. PCR was performed according to the manufacturer’s recommendations (GoTag G2 Hot Start DNA Polymerase protocol, Promega, Madison, WI, USA). PCR products were purified using the EPPIC Fast kit (A&A Biotechnology, Gdynia, Poland) and sequenced directly using the BigDye v3.1 kit (Applied Biosystems, Foster City, CA, USA) with an ABI PRISM 3130xl genetic analyzer (Applied Biosystems, Foster City, CA, USA). The sequences were analyzed manually and with the use of Mutation Surveyor software (SoftGenetics, State College, PA, USA). All detected mutations were confirmed by sequencing in two directions.

Additional molecular analyses. The analysis of the JAK2V617F mutation and BCR-ABL transcript was performed using real-time quantitative allele-specific RQ-PCR, and multiplex RT-PCR, respectively, as described before. The mutations in CALR exon 9, MPL exon 10, SRSF2 exon 1, U2AF1 exons 2 and 6, IDH1 exon 4, IDH2 exon 4, and ASXL1 exon 13 were screened with the use of the established high-resolution melting (HRM) assays and verified by Sanger sequencing as described before.

To verify whether two mutations found in the CLL-2423 sample are located in one or two different alleles, we sequenced individual colonies obtained from the sample. Briefly, MIR142 was amplified by PCR with the following primers MIR142_F 5’-TAACTACGCGGCCGATCTCCGAAACAGTAC, MIR142_R 5’-TCCACTACGGAAATTCGAGCAAGCAGTCGAGCAGTCAGG introducing the NotI and EcoRI restriction enzyme sites, respectively; PCR product was digested, gel purified, ligated into the pCDH-CMV-MCS-EF1-copGFP-T2A-Puro expression plasmid (CD513b-1, System Biosciences, Mountain View, CA, USA), and propagated in MAX Efficiency® E. coli Competent Cells (Invitrogen, Carlsbad, CA, USA). Individual colonies (N = 10) after MIR142 PCR amplification were sequenced using the Sanger method as described above. The sequencing revealed 6 clones with both identified mutations and 4 clones with the wild-type sequence.

Results and discussion

To determine the occurrence of mutations in MIR142 in MPNs, we analyzed a collection of 672 samples consisting of ET (n = 321), PV (n = 174), CML (n = 107), and PMF (n = 70). Additionally, we included CLL (n = 210) and AML (n = 47) samples, diseases for which the mutations in MIR142 have been reported. Screening was performed by Sanger sequencing of a PCR-amplified DNA fragment encompassing the MIR142 gene (defined as described above). Altogether, we identified only 3 mutations: one mutation [chr17:58331257G>T[-]]; n.62C>A not reported before was identified in a PMF sample (PMF_19 patient; 1/70); two other mutations [chr17:58331286A>G[-], n.33T>C and chr17:58331260A>G[-], n.59T>C] were identified in one CLL sample (CLL_2423 patient; 1/210). The n.62C>A mutation is located in the miR-142-3p post-seed region in a symmetric one-nucleotide-bulge structure (Fig. 1A and C). Although the mutation does not induce any apparent change in the predicted secondary structure of the miRNA precursor, it may influence miRNA:target interactions as well as the stability of the miRNA itself. Both mutations identified in the CLL sample are located in two established hotspots (n.33T>C, n.59T>C) and were previously described in CLL. Both mutations are in the mature miRNA duplex, specifically in the seed region of miR-142-3p and in the post-seed region of miR-142-5p (Fig. 1A). Cloning of the PCR product and subsequent sequencing of individual clones revealed that both mutations are located in the same allele (6 out of 10 sequenced clones). TargetScan analysis predicted that the n.59T>C mutation severely affects miR-142-3p target recognition, disabling recognition of 55% (139/250) of its targets and creating 79 new targets. Whereas, analysis of the n.33T>C mutation showed that it substantially affects the structure of the miRNA precursor (Fig. 1B) and hence very likely affects processing of the precursor.
and miRNA release. All identified mutations have increased functional weight scores resulting from a location in crucial miRNA precursor elements (based on miRMut criteria defined before)^4^,^35^,^36^.

Briefly, the PMF_19 patient, a male aged 57 years old, was diagnosed with PMF grade 3 (MF3), with a bone marrow blast content of 3.5% and intermediate 2 risk of unfavorable disease outcome according to the Dynamic International Prognostic Scoring System. The patient had a normal karyotype, was negative for the BCR-ABL transcript, and was triple-negative for driver mutations (CALR exon 9, JAK2 exon 12 and 14, and MPL exon 10), which is characteristic of up to 10% of PMF cases, usually with a less favorable prognosis^39^.

Additionally, molecular analysis of ASXL1 and U2AF1 genes revealed c.1904_1927dup (p. Glu635_Gly642dup) in the former and c.470A>G (p.Gln157Arg) in the latter, which are considered unfavorable prognostic factors^40^.

The CLL_2423 patient, a male aged 62 years old, was diagnosed with B cell CLL (IV stage according to Rai classification). No chromosome alteration was observed by nuclear FISH (including the chr17p/TP53 gene). After 6 cycles of immunochemotherapy (Rituximab, cyclophosphamide, dexamethasone protocol), complete

**Figure 1.** Characteristics of the MIR142 mutations detected in this study. (A) Locations of the mutations on the secondary stem-loop structure (predicted with mfold^37^) of the wild-type miR-142 precursor. Blue font indicates miRNA duplex, dark blue indicates seed regions, and black indicates flanking regions and terminal loop. Gray symbols represent mutations identified before (based on^4^), and red-circled symbols indicate mutations identified in this study^4^.

Secondary (above) and 3D (below) RNA structures adopted by the n.33T>C and n.59T>C mutant found in CLL. The 3D mutant structure (blue) is aligned with the corresponding wild-type structure (black). The mutations are indicated in red. The 3D structures were generated using RNAComposer^38^ and visualized in PyMOL (Schrödinger, LLC, New York, NY, USA). (C) Sanger sequencing results for wild-type and mutated samples.
hematologic remission was achieved in this case. Of interest, two events of further disease relapse were noted, the latter with coexisting hyperleukocytosis and TP53 deletion in 7% of nuclei tested.

As mentioned above, it was noticed before that MIR142 mutations observed in AML coincide with and are functionally related to the R140Q hotspot mutation in IDH2. However, in this study, we did not detect any IDH1/IDH2 mutation, generally observed in 4% of PMF cases, in any of the two samples (PMF_19, CLL_2423) with MIR142 mutations.

Together, our results show that mutations in MIR142 are generally very rare in MPN but that their frequency (~1.5%) in PMF may be in the range of that observed in CLL or AML. Nevertheless, further studies are needed to determine the real contribution of MIR142 mutations to PMF. Despite the mostly negative nature of our results, this study complements knowledge about the occurrence of MIR142 mutations in blood cancers and pancancer in general. Additionally, as functional studies of MIR142 mutations were performed only in AML, in which the mutations are relatively rare, the confirmed recurrence of mutations in other hematologic cancers indicates that further studies are needed to fully understand the role of these mutations, especially in malignancies in which they are the most frequent, i.e., DBCL and FL.

In summary, although we show that MIR142 mutations may occur in MPNs, particularly in PMF, the frequency is very low (~1.5%). We also confirmed the occurrence of MIR142 mutations in CLL, but similarly at a very low frequency.

Data availability
All data generated or analyzed during this study are included in this published article.

Received: 11 March 2022; Accepted: 20 June 2022
Published online: 28 June 2022

References
1. Elliott, K. & Larsson, E. Non-coding driver mutations in human cancer. Nat. Rev. Cancer https://doi.org/10.1038/s41568-021-00371-a (2021).
2. Tan, H. Somatic mutation in noncoding regions: The sound of silence. EBioMedicine 61, 103084 (2020).
3. Vinagre, J. et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 4, 2185 (2013).
4. Urbanek-Trzebiak, M. O. et al. Pan-cancer analysis of somatic mutations in miRNA genes. EBioMedicine 61, 103051 (2020).
5. Trussel, M. C. et al. MIR142 loss-of-function mutations derepress ASH1L to Increase HOXA gene expression and promote leukemogenesis. Cancer Res. 78, 3510–3521 (2018).
6. Marshall, A. et al. Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes. Sci. Rep. 10, 19390 (2020).
7. Kwanhian, W. et al. MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med. 1, 141–155 (2012).
8. Tolba, F. M., Foda, M. E., Kamal, H. M. & Elshabrawy, D. A. Expression of CD133, ABCG2, and MIR142 in acute leukemia. Sci. Rep. 4, 2185 (2013).
9. Shen, W.-W., Zeng, Z., Zhu, W.-X. & Fu, G.-H. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J. Mol. Med. Berl. Ger. 91, 989–1000 (2013).
10. Kramer, N. J. et al. Altered lymphopoiesis and immunodeficiency in miR-142 null mice. Blood 125, 3720–3730 (2015).
11. Xu, S. et al. miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control pro-Blooming macrophage program. Nat. Commun. 6, 8523 (2015).
12. Berrien-Elliott, M. M. et al. MicroRNA-142 is critical for the homeostasis and function of type I innate lymphoid cells. Immunity 51, 479–490.e6 (2019).
13. Zhou, L. et al. Epstein-Barr Virus (EBV)-BamHI-A Rightward Transcript (BART)-6 and Cellular MicroRNA-142 synergistically compromise immune defense of host cells in EBV-positive Burkitt lymphoma. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 22, 4114–4120 (2016).
14. Sun, Y. et al. Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood 117, 6172–6183 (2011).
15. Ito, J. et al. 141-lp regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Biochem. Biophys. Res. Commun. 418, 425–431 (2017).
16. Zhen, J. & Chen, W. MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice. Biomed. Pharmacother. Biomedicine Pharmacother. 97, 1479–1485 (2018).
17. Prestipino, A. et al. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med. 10, 7729 (2018).
18. Guru, S. A. et al. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Sci. Rep. 7, 43281 (2017).
19. Beillard, E. et al. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Hum. Cell 33, 1099–1111 (2020).
20. Larsen, T. S., Christensen, J. H., Hasselbalch, H. C. & Pallisgaard, N. The Jak2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br. J. Haematol. 136, 745–751 (2007).
21. Maradong, A. et al. Development of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17, 2474–2486 (2003).
22. Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379–2390 (2013).
23. Boyd, E. M. et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br. J. Haematol. 149, 250–257 (2010).
24. Lin, J. et al. Detection of SRSF2-P95 mutation by high-resolution melting curve analysis and its effect on prognosis in myelodysplastic syndrome. PLoS ONE 9, e115693 (2014).
25. Qian, J. et al. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS ONE 7, e45760 (2012).
26. Hatae, R. et al. Precise detection of IDH1/2 and BRAF hotspot mutations in clinical glioma tissues by a differential calculous analysis of high-resolution melting data. PLoS ONE 11, e0160489 (2016).
27. Pratcorona, M. et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 97, 388–392 (2012).
Acknowledgements
This work was supported by research grants from the Polish National Science Centre [2016/22/A/NZ2/00184 and 2020/39/B/NZ5/01970 (to P.K.); and 2020/39/D/NZ2/03106 (to P.G-M.)].

Author contributions
PG-M. – conceived the study, obtained financing, participated in the sample sequencing, performed most of the analyses, drafted the manuscript, and prepared the figure. Z.K. – performed the molecular analysis of the ASXL1 and U2AF1 genes and critically read and corrected the manuscript. A.T. – participated in the sample sequencing, analysis of the results, and in the manuscript preparation. W.W. – participated in the sample sequencing, analysis of the results, and in the manuscript preparation. K.G-B. – prepared and checked the samples quality and critically read and corrected the manuscript. L.H. – prepared the blood cancer samples and critically read and corrected the manuscript. M.G. – discussed the study at all steps of the analyses, participated in the manuscript preparation, and critically read and corrected the manuscript. K.L. – supervised the clinical characterization of the samples, discussed the study at all steps of the analyses, and critically read and corrected the manuscript. P.K. – conceived the study, supervised and coordinated the study, obtained financing, and drafted the manuscript (with P.G-M.).

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to P.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022